(Q37609775)

21 August 2017

1 reference

title

Dopaminergic treatments for hyperprolactinaemia (English)

1 reference

21 August 2017

1 reference

Crosignani PG

1

1 reference

21 August 2017

Ferrari C

series ordinal

2

1 reference

21 August 2017

publication date

1 September 1990

1 reference

Bailliere's clinical obstetrics and gynaecology

21 August 2017

published in

1 reference

21 August 2017

volume

4

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

441-455

1 reference

Incidentally found small pituitary adenomas may have no effect on fertility

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Prolactin response to thyrotropin-releasing hormone in women with infertility and/or randomly elevated serum prolactin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Menstrual function and serum prolactin levels after long-term bromocriptine treatment of hyperprolactinaemic amenorrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Bromocriptine-induced regression of a suprasellar extending prolactinoma during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Successful Outcome of Ergocryptine-Induced Pregnancies in Twenty-One Women with Prolactin-Secreting Pituitary Adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Idiopathic hyperprolactinemia may include a distinct entity with a natural history different from that of prolactin adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: rapid regression of symptoms under bromocriptine. Case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Spontaneous pregnancies in hyperprolactinemic women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Is pregnancy the best treatment for hyperprolactinaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

The effect of multiparity on intrasellar prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Rapid improvement in visual field defects following bromocriptine treatment of patients with non-functioning pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Effect of Bromocriptine on Secretion and Morphology of Human Prolactin Cell Adenomas in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Dihydroergocriptine in management of microprolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Medical treatment of hyperprolactinaemic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Functional characterization of hypothalamic hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Cabergoline: long-acting oral treatment of hyperprolactinemic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Polycystic ovary syndrome: a changing perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Detailed assessment of big big prolactin in women with hyperprolactinemia and normal ovarian function

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Depot-bromocriptine treatment for prolactinomas and acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Women with prolactinoma--effect of pregnancy and lactation on serum prolactin and on tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

A possible role for prolactin in the control of human chorionic gonadotropin and estrogen secretion by the fetoplacental unit

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Hyperprolactinemia. Long-term effects of bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

The long-term effects of megavoltage radiotherapy as sole or combined therapy for large prolactinomas: studies with high definition computerized tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Hyperprolactinemia--a significant factor in female infertility

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Storage and release of secretory granules in human prolactinomas: modification by bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Heterogeneity of serum prolactin throughout the menstrual cycle and pregnancy in hyperprolactinemic women with normal ovarian function

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Two forms of glycosylated human prolactin have different pigeon crop sac-stimulating activities

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Pituitary tumors and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

The natural history of idiopathic hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Primary radiotherapy of prolactinomas. Eight- to 15-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Pituitary tumors secreting growth hormone and prolactin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Asymptomatic hyperprolactinaemia and prolactinoma in the general population--mass screening by paired assays of serum prolactin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Successful pregnancy in an acromegalic patient during 2-Br-alpha-ergocryptine (CB-154) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Pregnancy and the hyperprolactinemic woman

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Management of prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Normal Pregnancies after Treatment of Hyperprolactinemia with Bromoergocryptine, Despite Suspected Pituitary Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Giant invasive prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Long-term effect of a first pregnancy on the secretion of prolactin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Polymorphism of prolactin secreted by human prolactinoma cells: immunological, receptor binding, and biological properties of the glycosylated and nonglycosylated forms

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Resistance to bromocriptine in prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Return of menstruation and normalization of prolactin in hyperprolactinemic women with bromocriptine-induced pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Prolactin secretion and menstrual function after long-term bromocriptine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

The natural history of untreated hyperprolactinemia: a prospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

In Vivo Effects of Estrogen on Ovine Pituitaries: Prolactim and Growth Hormone Biosynthesis and Messenger Ribonucleic Acid Translation*

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

The natural history of untreated microprolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Drugs five years later. Bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

CV 205-502 treatment of hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

Natural history of microprolactinomas: six-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3552%2805%2980303-7

7 January 2021

10.1016/S0950-3552(05)80303-7

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fdxt36dbkvgztpzegd7xtjmu5i

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_fdxt36dbkvgztpzegd7xtjmu5i

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fdxt36dbkvgztpzegd7xtjmu5i

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/fdxt36dbkvgztpzegd7xtjmu5i

1 reference

30 July 2022